Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Reviewing the research presented in this article, it is evident that from an epidemiological perspective, it is important to evaluate the extent to which findings of sex and gender differences in Alzheimer's dementia (AD) are due to differences in longevity, survival bias, and comorbidities.
-
Blood-based biomarkers are promising tools for the diagnosis of Alzheimer disease (AD) at prodromal stages (mild cognitive impairment [MCI]) and are hoped to be implemented as screening tools for patients with cognitive complaints.
Why it matters
In 106 patients with mild cognitive impairment, higher blood levels of NfL, GFAP, and p-Tau181 at the start were linked to later progression to Alzheimer's dementia. The authors suggest combining these blood markers could help predict who will progress, but this was a single-center observational study.
-
Alzheimer's disease (AD) is a chronic neurodegenerative disease and the most common form of dementia, especially in the elderly.
Why it matters
This review examines whether drugs that inhibit the DYRK1A enzyme could be a treatment strategy for Alzheimer's disease, since the gene is overexpressed in Down syndrome and may contribute to neurodegeneration. The evidence comes from laboratory and computer studies, so this is early-stage research and no clinical trial results are reported.
-
At least 40% of all dementia has been linked to modifiable risk factors suggesting a clear potential for preventative approaches targeting these factors.
-
Alzheimer disease (AD) is characterized by progressive cognitive decline in older individuals accompanied by the presence of two pathological protein aggregates - amyloid-β and phosphorylated tau - in the brain.
-
Alzheimer's disease (AD) is the most common type of dementia characterized by the deposition of amyloid beta (Aβ) plaques and tau-neurofibrillary tangles in the brain.
-
Each of these subtypes is associated with differential 18 F-FDG PET findings.
-
People with Down syndrome (DS) have increased risk of Alzheimer disease (AD), presumably conferred through genetic predispositions arising from trisomy 21.
Why it matters
This review discusses how genes on chromosome 21 beyond amyloid precursor protein may contribute to Alzheimer's disease in Down syndrome through immune, blood vessel, and metabolic problems. The authors suggest these pathways could be targets for future drug or lifestyle trials, but no intervention was tested here.
-
Alzheimer's disease (AD) is one of the fastest growing cognitive decline-related neurological diseases.
-
Alzheimer's Disease (AD) is the most common cause of dementia.
-
Animal studies increasingly indicate that the gut microbiota composition and function can be involved in the pathophysiology and progression of Alzheimer's disease (AD) at multiple levels.
-
Alzheimer's disease (AD), being the number one in terms of dementia burden, is an insidious age-related neurodegenerative disease and is presently considered a global public health threat.
-
MTL 11C-acetate SUVR was significantly elevated in MCI compared to cognitively normal participants (P = 0.03; Cohen d = 1.76).
Why it matters
In this small cross-sectional pilot study of six participants with mild cognitive impairment and five cognitively normal participants, a marker of astrocyte activity was elevated in the medial temporal lobe in mild cognitive impairment and related to amyloid burden and worse cognitive measures. Being a small pilot imaging study, it does not show that targeting astrocyte activity affects the disease.
-
Alzheimer's disease (AD) is the foremost type of dementia that afflicts considerable morbidity and mortality in aged population.
-
In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF) amyloid beta42 (Aβ) levels consistent with the presence of Alzheimer's disease (AD) pathology.
Why it matters
This study aimed to develop an algorithm using non- or minimally invasive measures to identify healthy elderly people likely to have abnormal cerebrospinal fluid amyloid beta42, which could reduce the number of lumbar punctures needed for trial screening. It is about identifying candidates for trials, not about treating, curing, or preventing Alzheimer's disease.
-
Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional clinical symptom-based definition to a clinical-biological construct along a temporal continuum.
-
We found that both Adu and SUS reduced the total plaque area in the hippocampus to a similar degree, with no additive effect in the combination treatment (SUS+Adu).
-
Obesity is related to quantitative neuroimaging abnormalities including reduced gray matter volumes and impaired white matter microstructural integrity, although the underlying mechanisms are not well understood.
Why it matters
In 104 cognitively normal people without Alzheimer's biomarkers, obesity was linked to imaging signs of white matter neuroinflammation. This suggests obesity-related inflammation may be a modifiable risk factor, but the study did not test any treatment or show it prevents dementia.
-
The aging population is a significant social, medical and economic problem due to increasing prevalence of chronic diseases in elderly population.
-
Alzheimer's disease (AD) is the most common form of dementia characterized by presence of extracellular amyloid plaques and intracellular neurofibrillary tangles composed of tau protein.
-
This is the first trial of Kampo medicine designed to examine the efficacy of HJG for the cognitive dysfunction of patients with mild AD.
Why it matters
This is a protocol for a trial testing the traditional Japanese medicine hachimijiogan as an add-on treatment for mild Alzheimer's disease. No results on whether it helps cognitive dysfunction are available yet.
-
Alzheimer disease (AD) has an insidious onset and heterogeneous clinical symptoms.
Why it matters
This study examined whether combining plasma amyloid-beta 42 and total tau with a cognitive test (MoCA) could help diagnose probable Alzheimer disease, since standard biomarkers are expensive and invasive. It addresses diagnosis only and provides no information about treating, curing or preventing the disease.
-
Recent human genetic studies have challenged long standing hypotheses about the chain of events in Alzheimer's disease (AD), as the identification of genetic risk factors in microglial genes supports a causative role for microglia in the disease.
Why it matters
This review argues that genetic and single-cell studies point to microglia dysfunction as a central mechanism in Alzheimer's disease, supporting the idea of modulating microglial activity as a treatment approach. It is a review of existing evidence and does not itself test any treatment in patients.
-
40/100
The present findings suggest that amyloid-independent regional neurodegeneration might underlie relations of neuroticism and conscientiousness with AD.
Why it matters
Among 397 non-demented adults, neuroticism and conscientiousness were not associated with amyloid deposition or white matter hyperintensities, but higher neuroticism and lower conscientiousness were linked to reduced cortical thickness in Alzheimer-signature regions. This is about personality and brain structure, not about treating or preventing Alzheimer's disease.
-
Cerebral energy metabolism in Alzheimer disease (AD) has recently been given increasing attention.
Why it matters
In the APP/PS1 mouse model of Alzheimer disease, the study found alterations in lactate content and lactate transporters in the brain. This is animal research on energy metabolism and does not show any treatment, cure or prevention for people.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Deep Learning-Based Classification and Voxel-Based Visualization of Frontotemporal Dementia and Alzheimer's Disease
- A review on omics-based biomarkers discovery for Alzheimer's disease from the bioinformatics perspectives: Statistical approach vs machine learning approach
- The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
- Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
- Artificial intelligence and omics-based autoantibody profiling in dementia
- Engineered butyrate-producing yeasts mitigate Alzheimer-associated phenotypes
- Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue
- Identification of diabetes-related dementia: Longitudinal perfusion SPECT and amyloid PET studies
- Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study
- The Effectiveness of Vitamin E Treatment in Alzheimer's Disease